37 (0.32–0.41) 0.31 (0.27–0.45) 0.24 0.36 (0.28–0.45) 0.28 (0.22–0.32) 0.27 0.80

0.03* C18 OH 0.06 (0.03–0.10) 0.04 (0.03–0.08) 0.66 0.07 (0.03–0.11) 0.05 (0.03–0.11) 0.86 0.38 0.48 C18:1 0.64 (0.59–0.81) 0.74 (0.68–0.84) 0.13 0.64 (0.53–0.79) 0.73 (0.61–0.83) 0.24 0.76 0.92 C18:1 OH 0.03 (0.02–0.03) 0.02 (0.02–0.03) 0.42 0.02 (0.02–0.03) 0.02 (0.02–0.03) 0.95 0.84 0.43 C18:2 0.22 (0.18–0.33) 0.28 (0.22–0.32) 0.36 0.24 (0.21–0.28) 0.22 (0.17–0.30) 0.31 0.97 0.12 ^All values are in μmol/l. Results are reported in Median and Confidence Interval 95%. +p Values were calculated by Mann–Whitney Test. ‡p Values were calculated by Wilcoxon Rank Test. * Significant Result p < 0.05. Amino acids There was no difference found when the 4SC-202 levels of amino acids between the groups at the beginning

of the AE program were compared (Table 3). At the end of the exercise program a decrease in the levels of tyrosine and 3-Methyladenine Ornithine in the group of cases with respect to baseline was observed. In the control group there was no significant change when compared with their baseline. Finally, when comparing the final values between the groups there was only a significant decrease in tyrosine levels in the group of cases. Table 3 Baseline and End of Study Amino Acids in Controls and Cases   Baseline p+ End of the Study p+ A vs C‡ B vs D‡   Control (A) n = 15 Cases (B) n = 17   Control (C) n = 15 Case (D) n = 17       Alanine 213.00 (190.27 – 282.78) 238.00 (202.03 – 259.95) 0.59 240.00 (185.52 – 271.17) 208.00 (198.01 – SB-715992 clinical trial 234.00) 0.59 0.84 0.09 Arginine 46.90 (40.51 – 62.78) 46.70 (38.55 – 52.69) 0.50 51.50 (32.61 – click here 68.11) 49.60 (37.35 – 59.99) 0.80 0.84 0.37 Citrulline 18.10 (14.95 – 20.41) 15.40

(14.20 – 15.99) 0.15 16.00 (12.96 – 18.42) 14.30 (12.61 – 17.18) 0.38 0.07 0.27 Glycine 200.00 (188.53 – 243.23) 224 (184.30 281.66) 0.42 205.00 (184.78 – 224.29) 208.00 (298.03 – 245.96) 0.34 0.89 0.40 Leucine 101.00 (84.59 – 108.20) 95.50 (85.85 – 101.97) 0.53 96.80 (89.02 – 111.67) 95.60 (91.83 – 104.93) 0.74 0.63 0.78 Methionine 42.90 (36.81 – 45.96) 40.10 (36.15 – 44.36) 0.50 44.00 (34.53 – 48.14) 40.20 (30.41 – 44.89) 0.23 0.76 0.54 Ornithine 74.20 (66.33 – 81.85) 79.40 (75.70 – 84.46) 0.28 69.20 (60.00 – 72.21) 66.00 (59.23 – 70.15) 0.40 0.21 0.003* Phenylalanine 51.80 (44.61 – 53.71) 44.60 (43.20 – 49.09) 0.21 44.40 (40.06 – 49.91) 44.60 (42.90 – 47.67) 0.80 0.18 0.76 Tyrosine 49.80 (44.87 – 62.62) 45.50 (41.90 – 50.58) 0.26 45.90 (39.97 – 51.14) 41.50 (37.60 – 44.97) 0.05 0.16 0.05* Valine 123.00 (97.69 – 153.35) 115.00 (101.09 – 142.67) 0.71 121.00 (102.11 – 141.35) 111.00 (98.99 – 124.87) 0.27 0.56 0.30 ^ All values are in μmol/l. Results are reported in Median and 95% Confidence Interval. +p Values were calculated by Mann–Whitney Test. ‡p Values were calculated by Wilcoxon Rank Test.

We thus postulate that AD patients with svCVD (mixed this website AD) will demonstrate greater cognitive benefit with cognitive enhancers. In this study, we selleck chemical compared the effectiveness of cognitive enhancers

between AD patients with and without svCVD in a real-world tertiary clinic setting. 2 Methods 2.1 Study Design and Study Sample The study was a retrospective review of a prospective electronic clinical database of dementia patients with data on diagnosis, treatment, follow-up (monitoring), and cognitive and functional outcomes. The study was approved by the Institutional Review Board. The study sample included outpatients from a tertiary dementia clinic, who were enrolled between January 2006 and July 2013. Sociodemographic, clinical (including use of cognitive enhancers), and outcome information on these patients were recorded on our medical electronic database. We focused primarily on cognitive outcomes, and considered the cognitive enhancers acetylcholinesterase inhibitors and N-methyl-d aspartate (NMDA) antagonists. We queried the database for all dementia outpatients who satisfied the following inclusion criteria: diagnosis of mild to moderate AD based on Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV TR) criteria [19], clinical dementia rating (CDR) of 1–2 [20],

availability of neuroimaging Volasertib purchase data and Mini-Mental State Examination (MMSE) score [21], and treatment with cognitive enhancers for at least 6 months. Patients who had a break in the use of cognitive enhancers for more than 3 months were excluded from the study. Of 951 dementia

patients seen from January 2006 to July 2013, a total of 165 eligible patients were identified. Of these, 137 (83 %) patients had mixed AD (AD + svCVD) and 28 (17 %) patients had AD without svCVD (pure AD) (Fig. 1). Fig. 1 Flow diagram of eligible patient selection. MMSE Mini-Mental State Examination, MRI magnetic resonance imaging 2.2 Measurements AD was diagnosed based on tuclazepam the DSM-IV TR criteria. The presence of WMH on brain magnetic resonance imaging (MRI) was used as a surrogate marker for svCVD. WMH were semi-quantitatively rated using the modified-Fazekas scale on T2-weighted MRI images by an experienced clinician [22]. Periventricular WMH (pv-WMH) was graded as 0 = absence, 1 = ‘caps’ or thin lining, 2 = ‘halo’, and 3 = irregular pv-WMH extending into the white matter. Deep subcortical WMH (dsc-WMH) was rated as 0 = absence, 1 = punctuate foci, 2 = confluent foci and 3 = large confluent areas. Total score was obtained by the summation of pv-WMH and dsc-WMH in the right and left hemispheres for a total score of 12. AD patients with a total WMH score of ≥6 points were classified as mixed AD, and pure AD otherwise.

Figure 2 Dot-ELISA results of reactivities of pooled unadsorbed (A) and adsorbed learn more (B) swine convalescent sera against the three previously reported SS2 virulence-associated proteins MRP, EF, and GAPDH. BSA was used as a negative control. Use of adsorbed convalescent-phase sera to probe a genomic DNA expression library

of the SS2 isolate ZY05719 To provide tenfold coverage of a SS2 genome (2 × 106 bp), a plasmid library containing inserts whose average size is 2 kb would contain about 5.7 × 104 independent recombinants. The SS2 genomic library, prepared from strain ZY05719 isolated from a Sichuan SS2 outbreak (Table 1), in E. coli DH5α consisted of approximately 6 × 104 clones for each expression vector (pET30 a, b, and c). These three libraries were used for IVIAT selection with the adsorbed convalescent sera. During the primary screening, 300 of the most intensely selleck chemicals immunoreactive clones were selected. Following rigorous selection, 60 clones that continuously showed a strong positive reaction with the adsorbed convalescent-phase sera antibodies were identified. Their LY3023414 clinical trial immunoreactivity was confirmed by an additional screening, in which these clones were compared with clones bearing the vectors alone without any inserts present. The positive

clones were picked out and then cultured in broth. The presence of a cloned DNA insert in all 60 clones was confirmed by PCR analysis and sequencing. Table 1 Bacterial strains and plasmids used in this study Strains or plasmids Serotype, Genotype and/or phenotype Reference/source Strains     HA9801 serotype 2;cps2J+, mrp+, ef+, sly+, gapdh+, gdh+, orf2+ Jiangsu outbreak SS2 isolate, 1998, China ZY05719 serotype 2; cps2J+, mrp+, ef+, sly+, gapdh+, gdh+, orf2+ Sichuan outbreak SS2 isolate, 2005, China T15 serotype 2; cps2J+, mrp-, ef- The Netherlands Plasmids     pET30(abc) Expression vectors allowing cloning of fragments in each of three reading frames; Kanr Novagen pMRP pET30(a) with partial mrp gene amplified from strain ZY05719, and cloned into EcoRI and XhoI sites, in vector, Kanr This work pEF pET30(a) with partial ef gene amplified from strain ZY05719, and

Gefitinib solubility dmso cloned into EcoRI and XhoI sites, in vector, Kanr This work pGAPDH pET32(a) with partial gapdh gene amplified from strain ZY05719, and cloned into BamHI and SalI sites, in vector, Ampr Previous work Kanr, kanamycin-resistant; Ampr, ampicillin-resistant. Categorization of the IVI proteins according to the actual or putative functions of the genes identified by IVIAT The sequencing results showed that most of the immunoreactive clones contained only a portion of the coding sequence of the relevant protein, and that these 60 clones encoded 48 different proteins. The difference in the number of positive clones and proteins is due to several clones encoding the same protein. For instance, clones 6, 34, and 73 encoded the protein ysirk1.

Individual conjugates, were coupled with biotin and used for the fluorescence enzyme immune assay detection method (semi-automatic ImmunoCAP100, Phadia, selleck compound Freiburg, Germany). Serum-specific IgE is expressed in kilo unit per liter (kU/L) correlated with the WHO reference of human serum IgE (1 kU = 2.4 ng/mL). A seven-point dose–response calibration was performed for each IgE and IgG measurement. buy Entospletinib For ImmunoCAP-specific IgE, the limit of detection (LOD) of 0.02 kU/L for IgE and 0.2 mg/L for IgG and the limit of calibration of 100 kU/L for Commercial ImmunoCAP conjugates (K76, Phadia) used in routine clinical laboratories were applied in parallel with similar

analytical procedures (for the calibration curves and control sera). For validation of the assays, the following buy CHIR98014 controls were included: pooled positive and negative patient/control sera, analytical standards (also used as set points for quality control), HSA solution and biotin control samples. The measured day to day precision was <12 % RSD. The

assay validation was performed according to the good laboratory practice. Separate studies with HSA solution showed that IgE values above 0.02 kU/L and IgG values above 3 mg/L can be considered as specific (above means +2 RSD or 10 % analytical variation). The variability between the in-vapor method and the commercial assay method was: 0.5–20 %

(for lower and upper edge of failure) for the IgE values. For the IgG data, however, the values collected with commercial CAPs were continuously 5–35 % higher in all tested subjects. Total IgE antibodies were determined using respective commercial Uni-CAP from Phadia. Detection of MDI-bound to HSA The protein concentration of each test conjugate learn more was determined by the method of Bradford (BioRad, Germany). The concentrations were adjusted by dilution or limited evaporation on a speed-vac system. The conjugates were subjected to SDS-PAGE using a 9 % separation gel. The amount of MDI-bound to HSA was calculated from the intact protein shift using MALDI-TOF-MS (using CHCA-matrix) and compared with non-conjugated HSA. LC-MS/MS measurements Purified HSA was incubated with MDI and analyzed by MALDI-TOF mass spectrometry (Applied Biosystems, the Netherlands) to determine the mass shift of the intact protein. Additionally, the reacted HSA was digested with trypsin (without any further treatments, such as disulfide bond reduction). The digested mixtures were analyzed by liquid chromatography (LC)-mass spectrometry (MS) (Applied Biosystems, the Netherlands), and modified peptides were scanned using neutral loss and precursor ion scans. Interesting ions were analyzed again with product ion scans to identify them from their fragmentation spectra (data not shown).

This helps determine whether to proceed with the planned check details surgery [11]. As mentioned, hip fracture repair can be considered a non-emergency (but semi-urgent) surgery with a moderate cardiac risk (~5% perioperative cardiac events and mortality); the original five-step approach could then be adapted to a three-step algorithm for this clinical context. Figure 1 depicts the clinical pathway for preoperative cardiac assessment of patients with a MK1775 hip fracture. In order

to determine whether a patient is medically fit for the surgery, patients with a hip fracture should have complete history LY2874455 datasheet and physical examination; in addition, chest X-ray and standard 12-lead electrocardiography should be obtained. Fig. 1 Cardiac evaluation and care algorithm for semi-urgent hip repair (adapted from [13]for geriatric hip fracture repair) Step 1 Does the patient

have any active cardiac conditions? (modified from [11]) The ACC/AHA guidelines have identified four groups of active cardiac conditions that signify major perioperative risk for surgery and that warrant preoperative workup (Table 1). Patients with one selleck compound or more of these active cardiac conditions require further diagnostic evaluation and, possibly, therapeutic intervention. Of note, patients with underlying coronary artery disease are at higher than average risk of perioperative cardiac events. According

to the ACCC/AHA guidelines, a coronary artery disease patient is defined as one with a history of myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, or coronary arterial luminal obstruction documented by coronary angiography [11]. A patient with stable coronary artery disease and a functional capacity of four metabolic equivalents (METs) or above (Table 2) is considered medically fit for hip fracture repair surgery although elective surgery should be delayed for at least 6 months in patients with recent acute myocardial infarction. In a case series of 11 patients (mean age 78.2 years, female 73%) with recent myocardial infarction (3 to 23 days) who underwent hip fracture repair, 1- and 6-month mortality was 45.4% and 63.5%, respectively; the impact of recent ACS on the risk of perioperative cardiovascular events nonetheless remains unknown.

Mol Microbiol 2007, 64:1375–1390.CrossRefPubMed 40. Berggren RE, Wunderlich A, Ziegler E, Schleicher M, Duke RC, Looney D, Fang FC: HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant Salmonella. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10:489–495.CrossRefPubMed 41. Georgellis D, Kwon O, De Wulf P, Lin EC: Signal GANT61 clinical trial decay through a reverse phosphorelay in the Arc two-component signal transduction system. J Biol Chem 1998, 273:32864–32869.CrossRefPubMed 42. Kwon O, Georgellis D, Lin EC: Phosphorelay as the sole physiological route of signal

transmission by the arc two-component system of Escherichia coli. J Bacteriol 2000, 182:3858–3862.CrossRefPubMed 43. Malpica R, Franco B, Rodriguez C, Kwon O, Georgellis D: Identification of a quinone-sensitive redox switch in the ArcB sensor kinase. Proc Natl Acad Sci USA 2004, 101:13318–13323.CrossRefPubMed 44. Georgellis D, Kwon O, Lin EC: Amplification of signaling activity Bucladesine in vitro of the Arc two-component system of Escherichia coli by anaerobic metabolites. An in vitro study with different protein modules. J Biol Chem 1999, 274:35950–35954.CrossRefPubMed

45. Matsushika A, Mizuno T: A dual-signaling mechanism mediated by the ArcB hybrid sensor kinase containing the histidine-containing phosphotransfer domain in Escherichia coli. J Bacteriol 1998, 180:3973–3977.PubMed 46. Iuchi S, Lin EC: Purification and phosphorylation of the Arc regulatory components of Escherichia coli. J Bacteriol 1992, 174:5617–5623.PubMed 47. Halsey TA, Vazquez-Torres A, Gravdahl DJ, Fang FC, Libby SJ: The ferritin-like Dps protein is required for Salmonella enterica serovar Typhimurium Selleckchem Ilomastat oxidative stress resistance and virulence. Infect Immun 2004, 72:1155–1158.CrossRefPubMed

48. Jang S, Imlay JA: Micromolar intracellular hydrogen peroxide disrupts metabolism by damaging iron-sulfur enzymes. J Biol Chem 2007, 282:929–937.CrossRefPubMed 49. Carlioz A, Touati D: Isolation of superoxide dismutase mutants in Escherichia coli : is superoxide dismutase necessary for aerobic life? Embo J 1986, 5:623–630.PubMed 50. Datsenko KA, Wanner BL: One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. PNAS 2000, 97:6640–6645.CrossRefPubMed Adenosine triphosphate 51. Wei D, Li M, Zhang X, Xing L: An improvement of the site-directed mutagenesis method by combination of megaprimer, one-side PCR and DpnI treatment. Anal Biochem 2004, 331:401–403.CrossRefPubMed 52. Lu S, Manges AR, Xu Y, Fang FC, Riley LW: Analysis of virulence of clinical isolates of Salmonella enteritidis in vivo and in vitro. Infect Immun 1999, 67:5651–5657.PubMed 53. Macomber L, Rensing C, Imlay JA: Intracellular copper does not catalyze the formation of oxidative DNA damage in Escherichia coli. J Bacteriol 2007, 189:1616–1626.CrossRefPubMed 54. Muller PY, Janovjak H, Miserez AR, Dobbie Z: Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 2002, 32:1372–1374.PubMed 55.

Semi quantitative adherence assay Quantitative Biofilm production by the isolated strains was determined using a semi-quantitative adherence assay as described previously [13, 23]. An overnight culture grown in BHI at 37°C was diluted to 1:100 in BHI with 2% glucose (w/v). A total of 200 μl of these cell EPZ015666 chemical structure suspensions was transferred in a U-bottomed 96-well

microtiter plate (Nunc, Roskilde, Denmark). Wells with sterile BHI alone was served as negative control. Each strain was tested in triplicate. The plates were incubated aerobically at 37°C for 24 h than the microtiter wells were washed twice with phosphate-buffered saline (PBS) and dried. Adherent bacteria were fixed with 95% ethanol and stained with 1% (w/v) crystal violet solution (Merck, France) for 5 min.

The microplates were washed, air-dried and the optical density of each well was measured at 570 selleck chemicals llc nm (OD570) using an automated Multiskan reader (GIO. DE VITA E C, Rome, Italy). Biofilm formation was interpreted as follows: -: non-producer (OD570 < 0.120); +: weak producer (0.120 < OD570 < 0.240; ++: producer (0.240 < OD570 < 0.5) and +++: high producer (OD570 > 0.5) [24]. Adherence to human epithelial cells Human epidermoid carcinoma epithelial cells (Hep-2; ATCC CCL-23) and the respiratory epithelial cell line (A549) were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% foetal calf serum (GIBCO-BRL) containing 1% penicillin (5 μg/ml) and streptomycin (100 μg/ml) and incubated with 5% CO2 at 37°C. Cells (Hep-2 and A549) were before seeded at a density of 5 × 105 /ml on glass coverslips PF-01367338 clinical trial placed in 24-well plates. All experiments were performed at 85-90% confluent cell monolayers. Prior to each experiment, the monolayer was washed with PBS and incubated with DMEM medium without antibiotics for 24 h. Overnight bacterial cultures were diluted at 1/100 into BHI broth and incubated at 37°C with agitation

for approximately 2 h until the bacteria reached mid-log-phase. An aliquot of 100 μl of bacterial suspension of a density corresponding to approximately 2 × 106 CFU/ml was added to each cell. After incubation at 37°C for 3h, the coverslips were washed three times with PBS, fixed with methanol for 20 min, stained with Giemsa solution for 20 min and washed three times with PBS. Bacterial adherence to the cells was determined by light microscopy. For each coverslip, a minimum of 800 cells was inspected to determine the percentage of infected cells, and next, 60-100 cells with bacteria were inspected to assess the number of cell associated bacteria. For each strain, two independent experiments were performed with two coverslips each [25]. Uninfected cells were included as a negative control. Statistical analysis Statistical analysis was performed on SPSS v.17.0 statistics software. Pearson’s chi-square χ2 test was used to assess inter-group significance. In addition Statistical significance was set at P < 0.05.

J Am Coll Surg 2014, 218:846–54.PubMedCrossRef 13. Chen M, Geng JG: P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp (Warsz) 2006, 54:75–84.CrossRef 14. Osborne NH, Wakefield

TW, Henke PK: Venous thromboembolism in cancer patients undergoing major surgery. Ann Surg Oncol 2008, 15:3567–78.PubMedCrossRef 15. Van Hemelrijck M, Adolfsson www.selleckchem.com/products/bmn-673.html J, Garmo H, Bill-Axelson A, Bratt O, Ingelsson E, Lambe M, Stattin P, Holmberg L: Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol 2010, 11:450–8.PubMedCrossRefPubMedCentral 16. Van Hemelrijck M, Garmo H, Holmberg L, Bill-Axelson A, Carlsson S, Akre O, Stattin P, Adolfsson J: Thromboembolic events following surgery for prostate cancer. Eur Urol 2013, 63:354–63.PubMedCrossRef 17. Hu JC, Gu X, VS-4718 Lipsitz SR, Barry MJ, D’Amico AV, Weinberg AC, Keating NL: Comparative effectiveness of minimally invasive vs open radical prostatectomy.

JAMA 2009, 302:1557–64.PubMedCrossRef 18. Mandala M, Falanga A, Roila F: Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol 2011, 22(6):vi85–92.PubMed 19. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM: Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012, 141:e227S–77S.PubMedCrossRefPubMedCentral 20. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, AUY-922 Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A: Venous thromboembolism prophylaxis

and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2013, 31:2189–204.PubMedCrossRef 21. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW: Prevention of venous thromboembolism: Phosphoglycerate kinase American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:381S–453S.PubMedCrossRef 22. Siragusa S, Armani U, Carpenedo M, Falanga A, Fulfaro F, Imberti D, Laurora R, Molinari AC, Prisco D, Silingardi M, Verso M, Visona A: Prevention of venous thromboembolism in patients with cancer: guidelines of the Italian society for haemostasis and thrombosis (SISET). Thromb Res 2012, 129:e171–6.PubMedCrossRef 23. Baron TH, Kamath PS, McBane RD: Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013, 368:2113–24.PubMedCrossRef 24.

Occup Environ Med 63(2):113–120CrossRef Martimo KP, Shiri R, Miranda H, Ketola R, Varonen H, Viikari-Juntura E (2009) Self-reported productivity loss among workers with upper extremity disorders. Scand J Work Environ Health 35(4):301–308CrossRef Martimo KP, Shiri R, Miranda H, Ketola R, Varonen H, Viikari-Juntura E (2010) Effectiveness of an ergonomic intervention on the productivity of workers with upper-extremity

disorders—a randomized controlled trial. Scand J Work Environ Health 36(1):25–33CrossRef McEwen B (1998) Stress, adaptation and disease: allostasis and allostatic load. Ann NY Acad Sci 840(1):33–34CrossRef McNutt LA, Wu C, Xue X, Hafner JP (2003) Estimating the relative risk in cohort studies and Selleckchem EX527 clinical trials of common outcomes. Am J Epidemiol 157(10):940–943CrossRef Neupane S, Virtanen P, Leino-Arjas P, Miranda H, Siukola A, Nygard CH (2012) Multi-site pain and working conditions learn more as predictors of work

ability in a 4-year follow-up among food industry employees. Eur J Pain 3:444–451 see more Radkiewics PW-BM (2005) Psychometric properties of work ability index in the light of comparative survey study. Int Congr Ser 1280:304–309CrossRef Rothman KJ, Greenland S, Lash TL (2008) Modern epidemiology. Lippincott Williams & Wilkins, Philadelphia Saltin G (1968) Phychological analysis of middle-aged and older former athletes. Comparison with still active athletes of the same ages. Circulation 38(6):1104–1115CrossRef

Skov T, Deddens J, Petersen MR, Endahl L (1998) Prevalence proportion ratios: estimation filipin and hypothesis testing. Int J Epidemiol 27(1):91–95CrossRef Sluiter JK, Frings-Dresen MH (2008) Quality of life and illness perception in working and sick-listed chronic RSI patients. Int Arch Occup Environ Health 81(4):495–501CrossRef Statistics Sweden (2008) http://​www.​seb.​se Statistics Sweden (2010) http://​www.​seb.​se Statistics Sweden (2011) http://​www.​seb.​se Stefansson C (2006) Major public health problems-mental ill health. Scand J Public Health 34(Suppl 67):87–103CrossRef Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D (2003a) Cost of lost productive work time among US workers with depression. JAMA 289(23):3135–3144CrossRef Stewart WF, Ricci JA, Chee E, Morganstein D (2003b) Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. J Occup Environ Med 45(12):1234–1246CrossRef Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R (2003c) Lost productive time and cost due to common pain conditions in the US workforce.